Metastasis Stage, Adjuvant Treatment, and Residual Tumor Are Prognostic Factors for Medulloblastoma in Children: Conclusions From the Children's Cancer Group 921 Randomized Phase III Study PURPOSE: To ...

ZetaMet™ (Zeta-BC-003) is a first-of-its kind molecular pathway designed to resolve metastatic cancer lesions, inhibit pain, and regenerate bone Phase 2a study examines the safety and efficacy of ...

Case study demonstrated resolution of lytic lesions, significant reduction in pain and prevention of fracture. ZetaMet™ is a first-of-its kind molecular pathway designed to suspend cancer, inhibit ...

Allogeneic SCT for myeloma may be curative for young patients, but its role remains controversial because of a reported high TRM in some series. Since 1991, we have performed 25 allografts for myeloma ...

Please provide your email address to receive an email when new articles are posted on . We were unable to process your request. Please try again later. If you continue to have this issue please ...

A 17-year-old girl presented to a hospital orthopedics department in Vietnam due to pain in her left hip joint, which she noted had been getting worse over the past month. Neither her personal nor her ...

A study suggests a new approach, or, possibly two new approaches against prostate cancer bone metastases: While targeted therapies and anti-cancer immunotherapies have not been especially successful ...

SYRACUSE, N.Y.--(BUSINESS WIRE)--Central New York Biotech Accelerator (CNYBAC) — Zetagen Therapeutics, Inc., a private, clinical stage, biopharmaceutical company focused on developing breakthrough ...

(690,000 patients annually are diagnosed with metastatic lytic bone lesions with only non-curative, palliative therapies available) SYRACUSE, N.Y. — Zetagen Therapeutics, Inc., a private, clinical ...